In the fast-paced world of medical technology, advancements are constantly being made to improve patient care and outcomes. One such innovation is Transpara Breast AI, developed by ScreenPoint Medical. This groundbreaking technology is enhancing breast cancer detection and reducing recall rates, providing a ‘second pair’ of eyes for radiologists. At the European Congress of Radiology (ECR) meeting in Vienna, ScreenPoint Medical is showcasing Transpara Breast AI and presenting real-world clinical results demonstrating its effectiveness.
Transpara has already shown significant clinical and workflow benefits in mammography screenings around the world. The results of four presentations and three posters being presented at ECR 2024 further validate its success. In a first-of-its-kind randomized controlled trial, researchers examined cancer detection rates and the types of detected cancers in the full MASAI-trial study population. The study found that AI-supported screening using Transpara resulted in significant improvements compared to double reading without AI. This breakthrough has the potential to revolutionize breast cancer detection and save lives.
Another prospective clinical trial evaluated the use of AI for workload reduction. By excluding low-risk cases for human reading and applying double reading to the remaining cases, researchers aimed to determine the value of AI in reducing reading workload without compromising performance. The study concluded that AI-based triaging led to a substantial reduction in reading workload without negatively affecting the accuracy of screenings. This finding has significant implications for radiologists, as it can improve overall efficiency and allow for more timely detection of high-risk cases.
Mark Koeniguer, CEO of ScreenPoint Medical, expressed his satisfaction with the positive feedback and data received from users and researchers. He emphasized that Transpara consistently delivers valuable results across different studies and settings. Koeniguer highlighted Transpara’s ability to effectively detect cancer early while maintaining consistent recall rates. This reassurance is crucial for women undergoing mammography screenings, as they should not have to compromise on the accuracy and effectiveness of their tests.
Transpara has gained regulatory approval from the FDA and the CE Mark, making it available for use with both 2D and 3D mammography from multiple manufacturers. With its user-friendly interface and ability to work concurrently with radiologists, Transpara has been widely adopted by hundreds of leading centers in over 30 countries. Research has shown that up to 45% of interval cancers, which occur between regular screenings, can be detected earlier using Transpara. This breakthrough technology not only improves detection rates but also enhances reading workflow, allowing radiologists to provide better patient care.
ScreenPoint Medical is dedicated to translating cutting-edge machine learning research into practical tools that can be used by radiologists. By partnering with experts in machine learning and incorporating feedback from renowned breast imagers, Transpara has become a trusted and effective solution for improving screening workflow, decision confidence, and breast cancer risk assessment.
As the field of medical technology advances, technologies like Transpara Breast AI are disrupting traditional screening methods and offering new possibilities for early cancer detection. With its proven clinical results and widespread adoption, Transpara is poised to make a significant impact on the future of breast cancer screening. The continued innovation in this field brings hope to countless women worldwide by improving outcomes and saving lives.
Sources:
Use the share button below if you liked it.